{
    "clinical_study": {
        "@rank": "55516", 
        "arm_group": [
            {
                "arm_group_label": "Order 1", 
                "arm_group_type": "Experimental", 
                "description": "Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7)."
            }, 
            {
                "arm_group_label": "Order 2", 
                "arm_group_type": "Experimental", 
                "description": "Subjects assigned to this arm will receive Placebo Nasal Spray first (Week 1), followed by Nicotine Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7)."
            }, 
            {
                "arm_group_label": "Order 3", 
                "arm_group_type": "Experimental", 
                "description": "Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Placebo Varenicline (Weeks 6-7)."
            }, 
            {
                "arm_group_label": "Order 4", 
                "arm_group_type": "Experimental", 
                "description": "Subjects assigned to this arm will receive Nicotine Nasal Spray first (Week 1), followed by Placebo Nasal Spray (Week 2), followed by Placebo Varenicline (Weeks 3-4), followed by a washout period (Week 5) and then Varenicline (Weeks 6-7)."
            }
        ], 
        "brief_summary": {
            "textblock": "Smoking prevalence is over 83% in methadone-maintained patients. These patients experience\n      significant difficulty quitting, and there is evidence that a majority of\n      methadone-maintained patients smoke most of their cigarettes in the 4 hours following\n      methadone dosing. The objective is to provide a preliminary test of the ability of two\n      pharmacological treatments, the nicotine nasal spray and varenicline, relative to  placebos,\n      to reduce smoking during the 4 hours following methadone dosing."
        }, 
        "brief_title": "Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained Patients", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Cigarette Smoking", 
            "Methadone Maintenance"
        ], 
        "condition_browse": {
            "mesh_term": "Smoking"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. be male or female, 18 years of age or older\n\n          2. be able to understand the study, and having understood, provide written informed\n             consent in English\n\n          3. have been enrolled in the UCPC-OTP program for at least 3 months and be stable on the\n             current methadone dose for at least a month\n\n          4. have smoked cigarettes for at least 3 months, have a measured exhaled CO level > 8\n             ppm, and not planning to seek smoking-cessation treatment within the next 3 months\n\n          5. have a willingness to comply with all study procedures, including trying to stop\n             smoking during designated weeks, and to comply with medication instructions\n\n          6. based on a week of SmokeSignals\u00ae cigarette pack assessments, smoke > 10\n             cigarettes/day and smoke at least 40% of daily cigarettes within the 4 hour\n             post-methadone-dosing period\n\n          7. if female and of child bearing potential, agree to use one of the following methods\n             of birth control: oral contraceptives, contraceptive patch, barrier (diaphragm or\n             condom), intrauterine contraceptive system, levonorgestrel implant,\n             medroxyprogesterone acetate contraceptive injection, complete abstinence from sexual\n             intercourse, hormonal vaginal contraceptive ring.\n\n        Exclusion Criteria:\n\n          1. have a current or past diagnosis of any psychotic disorder, or bipolar  I or II\n             disorder\n\n          2. have a psychiatric condition that, in the judgment of the study physician would make\n             study participation unsafe or which would make treatment compliance difficult\n\n          3. be a significant suicidal/homicidal risk\n\n          4. have a positive urine drug screen for anything other than opioids\n\n          5. have a medical condition that, in the judgment of the study physician, would make\n             study participation unsafe or which would make treatment compliance difficult. Such\n             conditions include, but are not limited to:\n\n               -  liver function tests greater than 3X upper limit of normal\n\n               -  serum creatinine greater than 2 mg/dL\n\n          6. have had clinically significant cardiovascular or cerebrovascular disease within the\n             past 6 months or have clinically significant ECG abnormalities\n\n          7. have taken an investigational drug within 30 days before consent\n\n          8. be taking concomitant medications that are contraindicated for use with the NNS or\n             varenicline\n\n          9. be taking any concomitant medications that could increase the likelihood of smoking\n             cessation (such as wellbutrin or nortriptyline)\n\n         10. have a known or suspected hypersensitivity to varenicline or the NNS\n\n         11. use/have used smoking-cessation counseling programs or medication treatments\n             currently, or within 30 days before consent\n\n         12. have used electronic cigarettes or tobacco products, other than cigarettes, in the\n             week before consent\n\n         13. be pregnant or breastfeeding\n\n         14. be anyone who, in the judgment of the investigator, would not be expected to complete\n             the study protocol (e.g., due to relocation from the clinic area, probable\n             incarceration, etc.)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147132", 
            "org_study_id": "2013-7275"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Order 1", 
                    "Order 2", 
                    "Order 3", 
                    "Order 4"
                ], 
                "description": "7 days. 1 mg/dose, up to 40x/day.", 
                "intervention_name": "Nicotine Nasal Spray", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Order 1", 
                    "Order 2", 
                    "Order 3", 
                    "Order 4"
                ], 
                "description": "14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.", 
                "intervention_name": "Varenicline", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Order 1", 
                    "Order 2", 
                    "Order 3", 
                    "Order 4"
                ], 
                "description": "7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear identical to the Nicotine Nasal Spray, but will be a placebo.", 
                "intervention_name": "Placebo Nasal Spray", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Order 1", 
                    "Order 2", 
                    "Order 3", 
                    "Order 4"
                ], 
                "description": "14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.", 
                "intervention_name": "Placebo Varenicline", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Methadone", 
                "Nicotine polacrilex", 
                "Nicotine", 
                "Varenicline"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Cigarette", 
            "Methadone", 
            "Smoking", 
            "Cessation", 
            "Varenicline", 
            "Nicotine"
        ], 
        "lastchanged_date": "May 21, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45229"
                }, 
                "name": "UC Physicians Company, LLC Opioid Treatment Program"
            }, 
            "status": "Active, not recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "A Pilot Randomized, Placebo-Controlled, Crossover Study of the Effect of the Nicotine Nasal Spray and Varenicline on Cigarette Smoking Following Methadone Dosing in Methadone-Maintained Patients", 
        "overall_contact": {
            "email": "theobajy@ucmail.uc.edu", 
            "last_name": "Jeffrey Theobald", 
            "phone": "513-585-8281"
        }, 
        "overall_official": {
            "affiliation": "University of Cincinnati", 
            "last_name": "Theresa Winhusen, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: University of Cincinnati IRB"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Subjects will be given a special electronic cigarette pack called SmokeSignals (copyrighted and manufactured by LIFETECHniques in Santa Barbara, CA).The electronic pack will hold a regular pack of cigarettes and will be able to record each time the pack opens and a cigarette is dispensed. Data will be sent to a password protected website at each study visit. This will measure how many cigarettes are smoked and when.", 
            "measure": "Proportion of daily cigarettes smoked in the 4 hours after receiving methadone dose", 
            "safety_issue": "No", 
            "time_frame": "7 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147132"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Cincinnati", 
            "investigator_full_name": "Theresa Winhusen", 
            "investigator_title": "Ph.D", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "The SmokeSignals pack will measure how many cigarettes are smoked per day. In addition to the SmokeSignals pack measurement, the Timeline Follow Back (TLFB) form will be filled out for each subject to measure use, as well.", 
                "measure": "Cigarettes per day", 
                "safety_issue": "No", 
                "time_frame": "7 weeks"
            }, 
            {
                "description": "Carbon monoxide (CO) in each participant's breath will be tested. A CO level less than or equal to 8 parts-per-million will be used to verify reports of no smoking.", 
                "measure": "Carbon monoxide level", 
                "safety_issue": "No", 
                "time_frame": "up to 8 weeks"
            }
        ], 
        "source": "University of Cincinnati", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Cincinnati", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}